Cargando…
Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy an...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719185/ https://www.ncbi.nlm.nih.gov/pubmed/35763351 http://dx.doi.org/10.1136/bmjopen-2021-052922 |
_version_ | 1784624882829492224 |
---|---|
author | Høgh, Stinne Hegaard, Hanne Kristine Renault, Kristina Martha Cvetanovska, Eleonora Kjærbye-Thygesen, Anette Juul, Anders Borgsted, Camilla Bjertrup, Anne Juul Miskowiak, Kamilla Woznica Væver, Mette Skovgaard Stenbæk, Dea Siggaard Dam, Vibeke Høyrup Binder, Elisabeth Ozenne, Brice Mehta, Divya Frokjaer, Vibe G |
author_facet | Høgh, Stinne Hegaard, Hanne Kristine Renault, Kristina Martha Cvetanovska, Eleonora Kjærbye-Thygesen, Anette Juul, Anders Borgsted, Camilla Bjertrup, Anne Juul Miskowiak, Kamilla Woznica Væver, Mette Skovgaard Stenbæk, Dea Siggaard Dam, Vibeke Høyrup Binder, Elisabeth Ozenne, Brice Mehta, Divya Frokjaer, Vibe G |
author_sort | Høgh, Stinne |
collection | PubMed |
description | INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy and postpartum. This trial aims to evaluate the preventive effect of 3 weeks transdermal estradiol treatment immediately postpartum on depressive episodes in women at high risk for developing postpartum depression. METHODS AND ANALYSIS: The Maternal Mental Health Trial is a double-blind, randomised and placebo-controlled clinical trial. The trial involves three departments of obstetrics organised under Copenhagen University Hospital in Denmark. Women who are singleton pregnant with a history of perinatal depression are eligible to participate. Participants will be randomised to receive either transdermal estradiol patches (200 µg/day) or placebo patches for 3 weeks immediately postpartum. The primary outcome is clinical depression, according to the Diagnostic and Statistical Manual of Mental Disorders-V criteria of Major Depressive Disorder with onset at any time between 0 and 6 months postpartum. Secondary outcomes include, but are not limited to, symptoms of depression postpartum, exclusive breastfeeding, cortisol dynamics, maternal distress sensitivity and cognitive function. The primary statistical analysis will be performed based on the intention-to-treat principle. With the inclusion of 220 participants and a 20% expected dropout rate, we anticipate 80% power to detect a 50% reduction in postpartum depressive episodes while controlling the type 1 error at 5%. ETHICS AND DISSEMINATION: The study protocol is approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Centre for Data Protection Compliance in the Capital Region of Denmark. We will present results at scientific meetings and in peer-reviewed journals and in other formats to engage policymakers and the public. TRIAL REGISTRATION NUMBER: NCT04685148. |
format | Online Article Text |
id | pubmed-8719185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-87191852022-01-12 Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial Høgh, Stinne Hegaard, Hanne Kristine Renault, Kristina Martha Cvetanovska, Eleonora Kjærbye-Thygesen, Anette Juul, Anders Borgsted, Camilla Bjertrup, Anne Juul Miskowiak, Kamilla Woznica Væver, Mette Skovgaard Stenbæk, Dea Siggaard Dam, Vibeke Høyrup Binder, Elisabeth Ozenne, Brice Mehta, Divya Frokjaer, Vibe G BMJ Open Mental Health INTRODUCTION: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy and postpartum. This trial aims to evaluate the preventive effect of 3 weeks transdermal estradiol treatment immediately postpartum on depressive episodes in women at high risk for developing postpartum depression. METHODS AND ANALYSIS: The Maternal Mental Health Trial is a double-blind, randomised and placebo-controlled clinical trial. The trial involves three departments of obstetrics organised under Copenhagen University Hospital in Denmark. Women who are singleton pregnant with a history of perinatal depression are eligible to participate. Participants will be randomised to receive either transdermal estradiol patches (200 µg/day) or placebo patches for 3 weeks immediately postpartum. The primary outcome is clinical depression, according to the Diagnostic and Statistical Manual of Mental Disorders-V criteria of Major Depressive Disorder with onset at any time between 0 and 6 months postpartum. Secondary outcomes include, but are not limited to, symptoms of depression postpartum, exclusive breastfeeding, cortisol dynamics, maternal distress sensitivity and cognitive function. The primary statistical analysis will be performed based on the intention-to-treat principle. With the inclusion of 220 participants and a 20% expected dropout rate, we anticipate 80% power to detect a 50% reduction in postpartum depressive episodes while controlling the type 1 error at 5%. ETHICS AND DISSEMINATION: The study protocol is approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Centre for Data Protection Compliance in the Capital Region of Denmark. We will present results at scientific meetings and in peer-reviewed journals and in other formats to engage policymakers and the public. TRIAL REGISTRATION NUMBER: NCT04685148. BMJ Publishing Group 2021-12-30 /pmc/articles/PMC8719185/ /pubmed/35763351 http://dx.doi.org/10.1136/bmjopen-2021-052922 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Mental Health Høgh, Stinne Hegaard, Hanne Kristine Renault, Kristina Martha Cvetanovska, Eleonora Kjærbye-Thygesen, Anette Juul, Anders Borgsted, Camilla Bjertrup, Anne Juul Miskowiak, Kamilla Woznica Væver, Mette Skovgaard Stenbæk, Dea Siggaard Dam, Vibeke Høyrup Binder, Elisabeth Ozenne, Brice Mehta, Divya Frokjaer, Vibe G Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title | Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title_full | Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title_fullStr | Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title_full_unstemmed | Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title_short | Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial |
title_sort | short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled mama clinical trial |
topic | Mental Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719185/ https://www.ncbi.nlm.nih.gov/pubmed/35763351 http://dx.doi.org/10.1136/bmjopen-2021-052922 |
work_keys_str_mv | AT høghstinne shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT hegaardhannekristine shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT renaultkristinamartha shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT cvetanovskaeleonora shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT kjærbyethygesenanette shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT juulanders shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT borgstedcamilla shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT bjertrupannejuul shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT miskowiakkamillawoznica shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT vævermetteskovgaard shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT stenbækdeasiggaard shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT damvibekehøyrup shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT binderelisabeth shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT ozennebrice shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT mehtadivya shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial AT frokjaervibeg shorttermoestrogenasastrategytopreventpostpartumdepressioninhighriskwomenprotocolforthedoubleblindrandomisedplacebocontrolledmamaclinicaltrial |